S&P 500
7,674.00
+0.27%
Dow Jones
53,264.00
+0.85%
Nasdaq 100
29,309.30
+0.23%
Russell 2000
3,016.29
+0.77%
FTSE 100
10,817.60
+0.67%
Nikkei 225
65,976.50
+0.73%

Investing

SGMT logo Sagimet Biosciences : SGMT

SGMT

Stock Data

$10.25

Change up

$0.07 (0.69%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Sagimet Biosciences Inc. is a biopharmaceutical company focused on creating treatments for diseases linked to faulty lipid metabolism. Its main project, Denifanstat, targets conditions like nonalcoholic steatohepatitis and acne through the inhibition of fatty acid synthase (FASN). Additionally, Sagimet is working on a drug for various cancers. Originally named 3-V Biosciences, it rebranded in 2019 and operates from San Mateo, California, since its founding in 2006.

All Sagimet Biosciences Articles

1 Article